Telerehabilitation for CAR-T Cell Immunotherapy
This study is testing a system called Home Automated Telemanagement (HAT) for patients undergoing CAR-T cell immunotherapy for lymphoma or myeloma. The HAT system uses a device to guide you through exercise and diet plans, track your progress and symptoms, and help you communicate with your healthcare team. The study aims to see how easy the HAT system is to use and how well patients stick to their treatment plans. To join, you must be over 21, have lymphoma or myeloma, be planning to receive commercial FDA-approved CAR-T therapy, have a good performance status (ECOG 0-2), and have access to a phone. The study plans to enroll 40 participants.
- Study design
- This is an interventional study, meaning participants will receive a specific intervention (the HAT device). It plans to enroll 40 participants.
- What's involved
- You would follow personalized exercise and nutrition plans guided by an interactive touch-screen device. Your progress and symptoms would be monitored, and you would communicate with your healthcare providers.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your progress will be measured for up to 12 weeks after you complete your CAR-T procedures.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy
At a glance
Conditions
NCT07390071
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Huntsman Cancer Institute at University of Utah
Salt Lake City, Utahstudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Douglas Sborov, MD, MS · PRINCIPAL_INVESTIGATOR · Huntsman Cancer Institute
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- System Usability Score - Feasibilityup to 12 weeks after completion of the CAR-T procedures.
To assess the feasibility of a multimodal cancer telerehabilitation model in patients with hematologic malignancies undergoing CAR-T therapy by evaluating system usability, acceptability, and exercise adherence. This outcome measure will report the System Usability Score for home telerehabilitation in patients undergoing CAR-T therapy. The System Usability Scale (SUS) is a 10-item, 5-point Likert questionnaire that yields a single usability score on a 0-100 scale; the minimum possible score is 0 (worst perceived usability) and the maximum is 100 (best perceived usability). This outcome measure will report the mean System Usability Score at 12 weeks after completion of the CAR-T procedure.
- Adherence Indicators - Feasibilityup to 12 weeks after completion of the CAR-T procedures.
To assess the feasibility of a multimodal cancer telerehabilitation model in patients with hematologic malignancies undergoing CAR-T therapy by evaluating daily exercise logs. This outcome measure will report adherence based on daily exercise logs in patients utilizing the home telerehabilitation after undergoing CAR-T therapy. Adherence will be defined as the percentage of exercise sessions of the total number of prescribed exercise sessions.